Pacific Edge Limited · NZX:PEB
Pacific Edge — Investor Presentation (May 2026)
43 slides from Pacific Edge's investor presentation, May 8, 2026
Slide 1: Capital Raising Presentation
Capital Raising Presentation Dr Peter Meintjes Chief Executive Officer Grant Gibson Chief Financial Officer 8 May 2026 1
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation has been prepared by Pacific Edge Limited (PEL) solely to provide Forward-looking statements Effect of rounding interested parties with further information about PEL and its activities at the date of This presentation may contain forward-looking stat
Slide 3: 1. Pacific Edge Overview
1. PACIFIC EDGE OVERVIEW [sx | PacificEdge” CANCER DIAGNOSTICS
Slide 4: Executive Summary
EXECUTIVE SUMMARY SIGNIFICANT VALUE CREATION OPPORTUNITIES, SUPPORTED BY PRUDENT CAPITAL MANAGEMENT SCIENCE, TECH AND IP CLINICAL EVIDENCE KEY SHORT-TERM CATALYST Cxbladder tests are patented non-invasive Cxbladder tests are supported by a robust Draft LCD for Triage & potentially Triage Plus urine
Slide 5: Capital Raising Overview
CAPITAL RAISING OVERVIEW Pacific Edge Limited (NZX/ASX:PEB) (Pacific Edge or the Company) is a cancer diagnostics company that develops and commercializes non-invasive bladder cancer diagnostic and prognostic tests, sold primarily under the “Cxbladder” brand Pacific Edge The Company focuses on g
Slide 6: Capital Raising Overview (Continued)
CAPITAL RAISING OVERVIEW (CONTINUED) Anticipated publication of the draft LCD with clear policy language that demonstrates medical necessity of Cxbladder Triage and potentially Triage Plus Leveraging the draft LCD to seek claim-by-claim reimbursement from Novitas for hematuria testing that would
Slide 7: Unaudited FY26 Financial Information: Cash Burn Reduced on 1H 26
UNAUDITED FY 26 FINANCIAL INFORMATION: CASH BURN REDUCED ON 1H 261 24,190 18,783 $11.5M -$35.7M $2.4M COMMERCIAL OPERATING NET LOSS AFTER 2H 26 CASH GLOBAL TESTS2 TESTS -23.8% REVENUE TAX +19.3% BURN/MONTH -16.3% on FY 25 -47.4% on on FY 25 -27.7% ON 1H 26 on FY 25 FY 25 US Total Tests2 18,784, US C
Slide 8: Corporate Overview
CORPORATE OVERVIEW CORPORATE SNAPSHOT BOARD AND MANAGEMENT NZX Code: PEB Simon Flood (Chairman) is an investment and governance leader with global capital markets experience in London, Hong Kong and Singapore. Share Price: He has held senior executive roles with Mercury Asset Management / As at 8 Ma
Slide 9: Cxbladder: Tests to Rule Out Cancer or Prioritize Patients
CXBLADDER: TESTS TO RULE OUT CANCER OR PRIORITIZE PATIENTS THE PATIENT CARE PATHWAY >130,000 >5,000 >30 Grade A Patients that have used Urologists that have ordered Publications demonstrating AV, Evidence rating by the AUA4 in its Cxbladder Cxbladder CV or CU evidence 2025 Microhematuria Guideline 1
Slide 10: The Cxbladder Suite
THE CXBLADDER SUITE Hematuria Evaluation NMIBC1 Surveillance Cxbladder Product Triage Detect Triage Plus Monitor Surveillance Plus Product Summary Risk stratification of Adjunctive use with Risk stratification and Alternative to cystoscopy Alternative to cystoscopy for microhematuria patients to cys
Slide 11: Driving Economic Value for Patients, Hospitals and Payers
DRIVING ECONOMIC VALUE FOR PATIENTS, HOSPITALS AND PAYERS CXBLADDER DELIVERS CLINICAL UTILITY, PATIENT SATISFACTION AND ECONOMIC VALUE CANCER INCIDENCE IN MICROHEMATURIA PATIENTS CYSTOSCOPIES SAFELY AVOIDED USING CXBLADDER No cystoscopy Cystoscopy No cancer No cancer Cystoscopy No cancer Cystoscopy
Slide 12: Driving Strategic Value Through Product Innovation
DRIVING STRATEGIC VALUE THROUGH PRODUCT INNOVATION NEXT GENERATION TESTS HAVE SUPERIOR PERFORMANCE AND PRICING • Cxbladder Triage Plus has been analytically validated and clinically validated for all hematuria patients (micro and gross) • Triage Plus has provisional patents filed, AV published, CV p
Slide 13: 2. Commercial Pathway and Anticipated Medicare Re-Coverage
2. COMMERCIAL PATHWAY AND ANTICIPATED MEDICARE RE- COVERAGE 13
Slide 14: Summary of Novitas Contractor Advisory Committee – February 2026
SUMMARY OF NOVITAS CONTRACTOR ADVISORY COMMITTEE – FEBRUARY 2026 EXPERT PANELISTS HIGHLIGHT NEED FOR REVISIONS TO MEDICARE POLICY CXBLADDER EVIDENCE AS A DRIVER FOR CHANGE Strong The committee regularly noted the strong clinical evidence supporting Cxbladder clinical evidence Triage and Triage Plu
Slide 15: Anticipated Medicare Re-Coverage: Estimated Timelines
ANTICIPATED MEDICARE RE-COVERAGE: ESTIMATED TIMELINES DRAFT LCD RELEASE AND FINAL COVERAGE TIMELINES ARE AT THE DISCRETION OF NOVITAS MEDICARE COVERAGE REQUEST CATALYST CY2026 CY2027 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 STRATA Study (May 2024) L39365 Reconsideration request (Triage) AUA Microhematuria Guideline
Slide 16: US Commercial Payers: Medicare Policy Expected to Unlock Volumes
US COMMERCIAL PAYERS: MEDICARE POLICY EXPECTED TO UNLOCK VOLUMES THE US PRIVATE HEALTH INSURANCE MARKET IS A SIGNIFICANT OPPORTUNITY • Commercial payers are a significant opportunity covering almost four times more lives than Medicare. Microhematuria patients skew younger with commercial health insu
Slide 17: FY Volumes Fall Despite Medicare Policy Momentum
FY 26 VOLUMES FALL DESPITE MEDICARE POLICY MOMENTUM TEST VOLUMES BY TYPE (TLT*) FY 26 TOTAL LAB THROUGHPUT (TLT*) 100% 16% 15% 14% 12% • Global TLT of 24,190 for FY 26 down 16.3% on FY 25 after Medicare 90% 18% 2% 6% 6% 80% 0% 5% non-coverage determination, reduced reach of the sales force and 10% 1
Slide 18: Mounting Policy Momentum Yet to Lift US Volumes
MOUNTING POLICY MOMENTUM YET TO LIFT US VOLUMES US TOTAL LABORATORY THROUGHPUT SALES FORCE EFFICIENCY LAYS FOUNDATIONS FOR GROWTH Light shade: Clinical study and evaluation tests 15,962 • US operations have faced numerous challenges in FY 26: 16,000 Dark Shade: Commercial tests • Constant headwind o
Slide 19: Consolidating New Zealand and Developing Australia and SEA
CONSOLIDATING NEW ZEALAND AND DEVELOPING AUSTRALIA AND SEA APAC COMMERCIAL SOUTHEAST ASIA: BUSINESS DEVELOPMENT WITH EARLY WINS • APAC Commercial and Clinical Operations (excluding R&D costs) is • In Southeast Asia we are establishing a network of lab partners for trending towards profitability (on
Slide 20: 3. Outlook
3. OUTLOOK 20
Slide 21: Outlook
OUTLOOK POSITIONED TO UNLOCK VALUE THROUGH UPCOMING COMMERCIAL, CLINICAL AND INNOVATION MILESTONES INNOVATION DRIVES LONG-TERM CLINICAL EVIDENCE DRIVES VALUE CREATION COMMERCIAL CATALYSTS FOR NEAR- MEDIUM-TERM VALUE CREATION • Next generation products demonstrate superior TERM VALUE CREATION perform
Slide 22: 4. Capital Raising Overview
4. CAPITAL RAISING OVERVIEW 22
Slide 23: Capital Raising Overview
CAPITAL RAISING OVERVIEW Pacific Edge is undertaking an equity raise of NZ$24 million by way of the offer of new shares, comprising: A NZ$18 million Placement; and A NZ$6 million Retail Offer Proceeds from the Offer will provide capital to: Transaction strengthen the balance sheet to suppo
Slide 24: Timetable
TIMETABLE Placement (NZ time) Placement conducted under trading halt on the NZX and ASX Monday, 11 to Tuesday, 12 May 2026 Announcement of the Placement results and trading halt lifted on the NZX and ASX Wednesday, 13 May 2026 Settlement on the NZX Friday, 15 May 2026 Settlement on the ASX (if requi
Slide 25: 5. Key Risks
5. KEY RISKS 25
Slide 26: Key Risks
KEY RISKS IMPORTANT: Like any investment, there are risks associated with an investment in Pacific Edge shares. Before investing in Pacific Edge, you should be aware than an investment in Pacific Edge has a number of risks, some of which are specific to Pacific Edge and some of which relate to liste
Slide 27: Key Risks (Continued)
KEY RISKS (CONTINUED) Pacific Edge currently has a Medicare non-coverage determination for Triage, Triage Plus, Detect and Monitor, and no coverage determination for Surveillance Plus. Medicare previously accounted for the majority of Pacific Edge’s US test volumes and, therefore, a significant perc
Slide 28: Key Risks (Continued)
KEY RISKS (CONTINUED) Pacific Edge relies on laboratory operations, third party suppliers of test components, IT and technical systems to process and report results for Cxbladder tests. While the performance of Cxbladder has been demonstrated in various scientific journal publications, any change to
Slide 29: 6. Foreign Selling Restrictions
6. FOREIGN SELLING RESTRICTIONS 29
Slide 30: Foreign Selling Restrictions
FOREIGN SELLING RESTRICTIONS Offer Selling Restrictions This document does not constitute an offer of new ordinary shares ("New Shares") of Pacific Edge in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares, may not b
Slide 31: Foreign Selling Restrictions (Continued)
FOREIGN SELLING RESTRICTIONS (CONTINUED) Hong Kong WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in H
Slide 32: 7. Appendices – Appendix 1: Global Market Opportunity
7. APPENDICES APPENDIX 1: Global Market Opportunity 32
Slide 33: Bladder Cancer – A Significant Global Healthcare Challenge
BLADDER CANCER – A SIGNIFICANT GLOBAL HEALTHCARE CHALLENGE INCIDENCE PER 100,000 OF THE POPULATION <1.7 1.7 to 2.7 2.7 to 5.3 5.3 to 8.6 >8.6 1st 6th 9th Costliest cancer to Most common Most common treat on a per- cancer in men2 cancer world- patient basis1 wide2 ~614K >220K >50% Annual cases Annual
Slide 34: Cxbladder Market Opportunity
CXBLADDER MARKET OPPORTUNITY CXBLADDER OFFERS A SIGNIFICANT ADDRESSABLE GLOBAL MARKET ANNUALLY US$10.8b Global TAM1 PATIENT/DISEASE MANAGEMENT SURVEILLANCE (CLINICAL DECISION MAKING) (RDM2, TRM3, RECURRENCE) Present with Referred for Receive Annual cases of Population Living with bladder cancer TAM
Slide 35: Appendix 2: Financial Performance
APPENDIX 2: Financial Performance 35
Slide 36: Positioning Pacific Edge for Medicare Re-Coverage
POSITIONING PACIFIC EDGE FOR MEDICARE RE-COVERAGE COST SAVINGS MINIMIZE CASH BURN 2H 261 FY 261 FY 25 2H 26 vs FY 26 vs • Operating revenue fell after loss of Financial Period ($000)1 1H 261 Medicare and Medicare Advantage (Draft) (Draft) (Audited) 1H 26 FY 25 coverage and reduced test volumes Opera
Slide 37: Appendix 3: Clinical Studies
APPENDIX 3: Clinical Studies 37
Slide 38: Driving Clinical Value for Physicians, Hospitals and Payers
DRIVING CLINICAL VALUE FOR PHYSICIANS, HOSPITALS AND PAYERS COMPELLING CLINICAL EVIDENCE CHANGES CLINICAL PRACTICE, MEDICAL POLICY AND GUIDELINES STUDY TEST AND EVIDENCE PUBLICATION DATE (1) • Pacific Edge generates clinical evidence required 1. STRATA Clinical Utility - CU of Triage Published May 2
Slide 39: Independent Studies Supplement Our Evidence Portfolio
INDEPENDENT STUDIES SUPPLEMENT OUR EVIDENCE PORTFOLIO INVESTIGATOR INITIATED TRIALS AND INDEPENDENT STUDIES DELIVER CLINICAL UTILITY AT MODEST SCALE INDEPENDENT STUDY FOCUS INSTITUTION TEST AND EVIDENCE TYPE PUBLICATION DATE1 Real World Utility of Triage in MH: A Kaiser CU Triage (RWE) Q1 20262 Matc
Slide 40: Hematuria Evaluation Five Year Clinical Studies Roadmap
HEMATURIA EVALUATION FIVE YEAR CLINICAL STUDIES ROADMAP Pre Calendar year 2023 2024 2025 2026 2027 2028 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 DBL STRATA * DBL DRIVE * AUSSIE * microDRIVE * Pooled CV CREDIBLE * Legend: Pre-activation (docs, CTA etc) Publication Submit
Slide 41: Surveillance Five Year Clinical Studies Roadmap
SURVEILLANCE FIVE YEAR CLINICAL STUDIES ROADMAP Pre Calendar year 2023 2024 2025 2026 2027 2028 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 “The 1800”1 LOBSTER * OCTOPUS CAB2 * Legend: Pre-activation (docs, CTA etc) Publication Submitted * SIV DBL Records review / follow-u
Slide 42: Sources and Assumptions - Total Addressable Market
SOURCES AND ASSUMPTIONS - TOTAL ADDRESSABLE MARKET 42
Slide 43: For More Information
FOR MORE INFORMATION: Dr. Peter Meintjes Chief Executive Officer email: peter.meintjes@pelnz.com Grant Gibson Chief Financial Officer email: grant.gibson@pelnz.com Pacific Edge 87 St David Street, PO Box 56, Dunedin, New Zealand P +64 3 577 6733 Within NZ 0800 555 563 email: investors@pacificedge.co